UE-2343
- Generic Name
- UE-2343
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Phase 2
Recruiting
- Conditions
- Alzheimer DiseaseDementia ModerateDementia, Mild
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Actinogen Medical
- Target Recruit Count
- 220
- Registration Number
- NCT06125951
- Locations
- 🇺🇸
ACW Investigative Site 218, Carlsbad, California, United States
🇺🇸ACW Investigative Site 213, Orange, California, United States
🇺🇸ACW Investigative Site 209, Sherman Oaks, California, United States
Xanamemâ„¢ in Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Cerebrospinal FluidSafetyCognitive FunctionCentral Nervous SystemSmall Fibre NeuropathyElectrocardiographyPeripheral NeuropathyCortisolHealthy Ageing
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Actinogen Medical
- Target Recruit Count
- 42
- Registration Number
- NCT03830762
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Actinogen Medical
- Target Recruit Count
- 40
- Registration Number
- NCT02616445
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
A Phase I Study of Oral UE2343 in Healthy Subjects
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2013-07-17
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 48
- Registration Number
- NCT01770886
- Locations
- 🇬🇧
Simbec Research, Merthyr Tydfil, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath